Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder
Proto-Oncogene Proteins c-met
Urinary Bladder Neoplasms
Urinary sMet levels distinguish patients with BCa from those without, and patients with or without MIBCa, suggesting the potential utility of urinary sMet as a BCa biomarker for surveillance following initial treatment. Further studies are warranted to determine its potential value for prognosis in advanced disease, predicting treatment response, or identifying patients likely to benefit from Met-targeted therapies.